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Abstract
We recently demonstrated that ex vivo activation of SMAD-independent BMP4 signaling in 
hematopoietic stem/progenitor cells (HSPCs) influences their homing into the bone marrow (BM). 
We here assessed if alterations in BMP signaling in vivo affects adult hematopoiesis by affecting 
the BM niche. We demonstrate that systemic inhibition of SMAD-dependent BMP signaling by 
infusion of the BMP antagonist Noggin (NGN) significantly increased CXCL12 levels in BM 
plasma leading to enhanced homing and engraftment of transplanted HSPCs. Conversely, the 
infusion of BMP7 but not BMP4, resulted in decreased HSPC homing. Using ST2 cells as an in 
vitro model of BM niche, we found that incubation with neutralizing anti-BMP4 antibodies, NGN 
or dorsomorphin (DM) as well as knockdown of Smad1/5 and Bmp4, all enhanced CXCL12 
production. Chromatin immunoprecipitation identified the SMAD-binding element in the 
CXCL12 promoter to which SMAD4 binds. When deleted, increased CXCL12 promoter activity 
was observed, and NGN or DM no longer affected Cxcl12 expression. Interestingly, BMP7 
infusion resulted in mobilization of only short-term HSCs, likely because BMP7 affected CXCL12 
expression only in osteoblasts but not in other niche components. Hence, we describe SMAD-
dependent BMP signaling as a novel regulator of CXCL12 production in the BM niche, 
influencing HSPC homing, engraftment and mobilization.
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Introduction
Hematopoietic stem cell (HSC) transplantation is commonly used for the treatment of 
various forms of cancers, bone marrow failure, hereditary metabolic disorders and severe 
congenital immuno-deficiencies 1. Within the bone marrow (BM), HSCs interact with their 
microenvironment wherein they reside, also termed as “niche”. HSCs were initially 
proposed to be associated with osteoblasts 2, whereas subsequently many HSCs were shown 
to be associated with the sinusoidal endothelium 3. Hematopoietic reconstitution following 
transplantation requires that HSCs home efficiently into the BM niches. Secretion of 
multiple cytokines and growth factors from cells in the BM niche regulate HSC maintenance 
and differentiation 4. HSCs also express a series of adhesion receptors for which ligands are 
expressed on different cell types in the BM, allowing homing and retention of transplanted 
HSCs 5. Alterations in adhesion receptor expression or their interaction with corresponding 
ligands within the niche, not only leads to HSC mobilization, but also to poor HSC 
maintenance 6.
The chemokine CXCL12 and its G protein-coupled receptor (GPCR), CXCR4, play major 
roles in hematopoietic stem/progenitor cell (HSPC) migration into the BM as well as their 
retention within the niche 7-11. Mx-cre based conditional deletion of CXCR4 from adult 
murine HSCs, demonstrated that CXCR4 is important for the maintenance of primitive 
HSCs 10. This interaction is also important for homing of human and murine HSCs 
following transplantation in irradiated hosts 10, 11. A CXCL12 chemokine gradient, 
produced by BM niche cells, attracts transplanted HSCs, which first attach to and roll over 
the endothelium, followed by their penetration of the tissue via trans-endothelial 
migration 12. Depending upon the cell type wherein it is expressed, CXCL12 affects 
maintenance of HSCs and lineage-committed progenitors differently 13, 14.
Although an extensive body of work exists that has evaluated the turnover and inactivation 
of secreted CXCL12, less is known regarding the regulation of Cxcl12 gene expression. 
CXCL12 expression is elevated by hypoxic conditions, as a result of HIF-1α binding to its 
promoter 15. Inflammatory stimuli like IL-1 and IL-6 induce CXCL12 expression in a 
CCAAT/enhancer binding protein β (c/EBPβ)-dependent manner 16. In addition, the 
promoter region of Cxcl12 contains binding sites for Sp1, AP1, NFκB, PARP1, among 
others 17.
Bone Morphogenetic Proteins (BMPs) are major regulators of mesoderm specification and 
play important roles in the development of the hematopoietic system 18, 19. In addition, they 
play important roles in the formation and homeostasis of bone tissue, which constitute a 
crucial BM niche 20. Although it is well known that BMPs can modulate bone homeostasis 
in postnatal life 21, 22, and that the modulation of bone mass affects adult 
hematopoiesis 2, 23-25, it is not known if BMP-mediated changes in osteoblast biology 
directly affect HSPC function. Earlier, TGF-β was shown to affect Cxcl12 expression in 
stromal cell lines 26. Here, we demonstrate that the regulation of CXCL12 expression within 
the BM niche by SMAD-dependent BMP signaling affects homing and engraftment of 
HSCs, as well as mobilization of hematopoietic progenitors.
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Materials and methods
Animals
Six to eight week old C57BL/6J-CD45.2 (Centre d’Elevage R. Janvier, Le Genest-St Isle, 
France), B6.SJL-PTPRCA-CD45.1 (Charles River Laboratories, Raleigh, NC) and Col1a1-
GFP mice (driven by the 2.3kb rat procollagen type 1, alpha 1 (Col1a1) promoter, generated 
by David Rowe 27) were bred and maintained in the animal facility at KU Leuven. During 
the experiments, mice were maintained in isolator cages, fed with autoclaved acidified water 
and irradiated food ad libitum. All experiments were approved by the Institutional Ethics 
Committee.
Cell culture
Primary BM stroma and ST2 cells were used to determine the effect of SMAD signaling on 
CXCL12 expression. The cells were maintained in RPMI 1640 medium (Gibco laboratories, 
Grand Island, NY) containing 10% fetal bovine serum (FBS; Gibco laboratories) and 
antibiotics (1% penicillin/streptomycin; Gibco laboratories). 25,000 cells were cultured in 
each well of 24 well plates for 48h and the effect of BMP7/Dorsomorphin (DM; Sigma-
Aldrich)/noggin (NGN; R&D systems Inc., Minneapolis) was analyzed by performing 
quantitative RT-PCR (qRT-PCR). Alternatively, the cells were first transfected with the 
pGL3-basic vector containing a control or mutated CXCL12 promoter, and the effect of 
BMP7 (R&D Systems)/DM/Noggin was analyzed by performing dual luciferase assay.
FACS isolation of cellular components of the HSC niche
The cellular components of the BM niche were sorted using a system reported earlier 28. The 
detailed procedure can be found in the Supplementary methods.
qRT-PCR analysis
qRT-PCR was performed using standard protocols. The details of the procedures, reagents 
and the list of primers used are provided in the Supplementary methods.
esiRNA mediated knockdown of gene expression
The endoribonuclease-prepared siRNA targeting Smad1, Smad5 and Bmp4 were generated 
in the lab using published protocols 29. Briefly, the target region for esiRNA production was 
identified using the web server DEQOR 30, which assists in identifying regions in a gene 
that show high silencing capacity based on the base pair composition whilst assessing 
possible off target effects. As esiRNAs are a mixture of siRNAs, the off target effects are 
reduced, compared with the use of single siRNAs. The template for in vitro transcription 
was generated using cDNA from ST2 cells and specifically designed primers with a 5′ T7 
promoter sequence were used to amplify the cDNA fragment (primer sequences in 
Supplementary table). The tagged cDNA fragment was then used as a template for in vitro 
transcription using T7 enzyme and the resulting dsRNA was digested using GST-RNase III. 
The digested dsRNA was purified using Q-Sepharose beads and was directly used to 
transfect ST2 cells for gene knockdown.
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Luciferase Assay
A 3kb DNA sequence upstream of the Cxcl12 transcription start site was cloned upstream of 
the Luciferase gene in the pGL3-basic-vector (Promega, Madison, WI). ST2 cells were 
transfected with 5 μg of the plasmid containing the CXCL12 promoter as well as 0.5 μg of 
the control vector containing Renilla Luciferase (pRL-TK; Promega) and cultured with DM 
or Noggin. Firefly and Renilla Luciferase activities were assayed with the dual luciferase 
assay system (Promega) and Firefly Luciferase activity was normalized to Renilla 
Luciferase activity, as suggested by the manufacturer. All experiments were carried out in 
triplicate and repeated 3 times with consistent results.
Chromatin immunoprecipitation (ChIP) assay
ST2 cells were used to identify the binding site of SMAD4 to the CXCL12 promoter. ST2 
cells were cultured and processed for qChIP following a protocol published earlier 31 with 
some modifications. Details of the procedures are provided in the Supplementary methods.
Site directed mutagenesis
The Smad Binding Element (SBE) identified to be important for SMAD4 binding to the 
CXCL12 promoter was deleted using the Phusion site-directed mutagenesis kit (Thermo 
Scientific, Hudson, NH) according to the manufacturer’s instructions. For PCR we used the 
5_-phosphorylated primers listed in the Supplementary table. The PCR product was 
circularized with T4 DNA ligase and used for transforming E-coli competent cells. The 
resultant plasmids were sequenced to confirm the correct deletion of the targeted SBE.
Immuno-blotting
Immuno-blotting was performed using standard protocols and reagents. Details of the 
procedures and antibodies used are provided in the Supplementary methods. Band intensities 
were quantified using ImageJ 1.32 software (National Institutes of Health, Bethesda, MD) 
after densitometric scanning of the films, and normalized to β-actin or Histone-H3.
ELISA
ELISA was performed to quantify levels of CXCL12 in plasma from peripheral blood and 
BM of the mice infused with PBS/BMP7 (0.5mg/kg)/NGN (2mg/kg). To obtain BM plasma, 
hind limbs of mice were flushed with 200μl PBS. Cells were pelleted down and the plasma 
was used to quantify CXCL12 levels using the mouse CXCL12 ELISA immunoassay (R&D 
System, Minneapolis, MN) following the manufacturer’s instructions.
In vitro migration assays
In vitro trans-well migration assays were performed as described before with slight 
modifications 32. Details of the procedure are provided in the Supplementary methods 
section.
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Homing assays
The homing potential of Lin− BM cells in PBS/BMP7/NGN/DM (200 μg/mouse) infused 
mice was analyzed using protocols used by us before 33. Details of the protocols are 
provided in Supplementary methods.
Serial transplantation
50,000 freshly isolated total BM cells from CD45.1 mice were transplanted into sub-lethally 
irradiated (5Gy) PBS or NGN (2mg/kg) infused (24h prior to transplantation) C57BL/6J-
CD45.2 mice. For engraftment studies with mobilized HSPCs, peripheral blood (PB) cells 
were collected from CD45.1 mice injected with either PBS or BMP7 (0.5mg/kg) 24h prior. 
Mononuclear cells (MNCs) isolated from 1ml of PB were injected along with 1×105 
competitor CD45.2 BM cells into lethally irradiated (10Gy) C57BL/6J-CD45.2 mice. PB 
chimerism analysis was performed every 4 weeks. After 12 weeks, primary recipients were 
sacrificed, BM harvested, and 1×106 cells were grafted in two secondary lethally irradiated 
CD45.2 mice. After 3 months, chimerism in secondary recipients was evaluated. Mice with 
more than 1% multi-lineage chimerism were considered engrafted.
Flowcytometry
PB and BM chimerism and multi-lineage analysis was performed by flowcytometry. Details 
of the procedures as well the reagents used for staining are provided in the Supplementary 
methods.
Statistical analysis
Data are shown as mean ± SEM. Statistical analysis was performed using a 2-tailed 
Student’s t-test. P-values less than 0.05 were considered statistically significant. 
Significance of the data and differences between groups were also assessed using one-way 
ANOVA (with post hoc comparisons using Dunnett’s test) using a statistical software 
package (GraphPad Prism 5; San Diego, CA).
Results
Systemic inhibition of SMAD-dependent BMP signaling leads to enhanced homing and 
engraftment of HSPCs
To assess the role of SMAD-dependent BMP signaling in adult hematopoiesis, we 
intravenously infused sub-lethally irradiated CD45.2 mice with PBS/NGN. NGN binds to 
BMPs and inhibits the binding to their receptors 34. 50,000 BM cells from CD45.1 mice 
were transplanted in the treated CD45.2 mice to assess any change in engraftment in 
response to alteration of BMP signaling (Fig. 1a,b). We observed a consistent increase in 
donor-derived chimerism at 4, 8 and 12 weeks post-transplantation in primary recipients that 
were pre-infused with NGN. In addition, analyses of the secondary recipients showed a 3-
fold increase in long-term donor-derived chimerism with BM derived from NGN injected 
mice. These studies demonstrate that systemic inhibition of SMAD signaling leads to a 
significantly enhanced long-term repopulation ability of HSCs.
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To determine if the increased engraftment of HSPCs in NGN infused mice was due to 
enhanced homing, total BM cells or lin− cells were injected in lethally irradiated animals and 
the total number of colony forming cells (CFCs) homed within the BM after 16h of 
transplantation was enumerated and compared with the number of CFCs injected (Fig. 1c). 
The fraction of transplanted CFCs that homed into the BM was significantly higher in 
animals pre-treated with NGN. On the other hand, infusion of BMP7 but not BMP4 led to 
decreased homing of the transplanted HSPCs. We next examined the expression of key 
hematopoiesis regulators expressed within the niche in response to NGN infusion (Suppl. 
Fig. 1a). Twenty-four hours following infusion of PBS/NGN in mice, BM cells were 
isolated from the hind limb bones of mice following crushing and treatment with 
collagenase I. MACS-separated lin−CD45− BM niche cells were used to quantify gene 
expression by qRT-PCR. Amongst all the genes analyzed (Cd44, Cxcl12, Icam1, Vcam1, 
Mmp7, Mmp9, Upa, Ang1, Opn, Scf, Ccl2), we found that the expression of Cxcl12 was 
enhanced up to 2-fold following NGN infusion (Suppl. Fig. 1a). We repeated these 
experiments to analyze the status of SMAD signaling by assessing the expression of SMAD 
target genes in addition to Cxcl12 expression following the infusion of PBS/BMP7/NGN 
(Fig. 1d). Expression of the SMAD target genes Id2, Id3 and Runx2 increased following 
BMP7 injection, while their expression decreased upon injection of NGN compared with 
PBS injected controls, confirming modulation of SMAD-mediated BMP signaling in niche 
cells in response to the proteins injected (Fig. 1d). In addition, infusion of BMP7 increased 
the expression of SMAD target genes while decreasing the expression of Cxcl12 in 
lin−CD45− BM cells, contrary to the results from NGN infusion. We then tested if infusion 
of dorsomorphin (DM), a specific inhibitor of SMAD phosphorylation 35, mimicked the 
effect of NGN. We observed that infusion of DM also resulted in increased Cxcl12 
expression in lin−CD45− BM cells (Suppl. Fig. 1b). This was also associated with an 
enhanced proportion of transplanted CFCs that homed to the BM within 16h after 
transplantation (Suppl. Fig. 1c). We also assessed the secretion of CXCL12 protein by BM 
niche cells by performing ELISA on BM plasma (Fig. 1e). Consistent with gene expression, 
NGN and BMP7 also affected the levels of CXCL12 protein in BM plasma. We did not find 
any significant change in the CXCL12 levels in peripheral blood (PB; Fig. 1f).
Inhibition of SMAD-mediated BMP signaling enhances CXCL12 expression in BM stromal 
cells
As CXCL12 is the most important chemokine known to recruit HSCs to their niche, we 
addressed whether its altered expression could have led to increased migration of HSPCs 
towards NGN-treated niche cells. We used the murine BM stroma-derived cell line ST2 as 
an in vitro model and performed migration assays using a trans-well system (Fig. 2a). We 
assessed the chemotactic migration of lineage-depleted BM cells, labeled with PKH-26, 
towards ST2 cells either or not treated with NGN or DM. DM is a very potent small 
molecule inhibitor of BMP signaling and acts by selectively inhibiting BMP type I 
receptors. Inhibition of BMP signaling using DM led to increased migration of HSPCs 
towards ST2 cells (Fig. 2a). Addition of NGN also induced increased chemo-attraction of 
HSPCs to ST2 cells, suggesting autocrine regulation of the pathways involved. As 
intravenous (iv) infusion of BMP7 inhibited homing of transplanted HSPCs, we also 
analyzed the migration potential of HSPCs towards BMP7 treated ST2 cells. However, 
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unlike the in vivo effects of BMP7 on homing of HSPCs, we did not find any effect of 
BMP7 on migration in vitro.
As infusion of BMP7/NGN led to altered SMAD signaling and concomitantly changed the 
expression of Cxcl12 in the BM niche, we examined whether Cxcl12 expression was 
similarly altered in treated ST2 cells. Cxcl12 expression in ST2 cells, cultured for 2 days in 
the presence of the BMP inhibitors NGN or DM, was compared with that in carrier control 
by qRT-PCR (Fig. 2b). A significant increase in Cxcl12 expression in ST2 cells was 
observed upon inhibition of SMAD signaling by DM and NGN. We extended these findings 
by measuring the levels of CXCL12 protein in supernatant of ST2 cells treated with or 
without DM (Fig. 2c). Consistent with the gene expression data, we found increased levels 
of CXCL12 secretion by the ST2 cells cultured with DM compared with control. These 
results were further confirmed by performing luciferase promoter assays wherein the 
CXCL12 promoter was cloned upstream of the luciferase gene of the pGL3 vector. ST2 cells 
were transfected with the vector containing the CXCL12 promoter, and luciferase activity 
following treatment with carrier control or the inhibitors DM/NGN was assessed using a 
dual luciferase assay (Fig. 2d). Both NGN and DM enhanced CXCL12 promoter-mediated 
luciferase expression even if the effect of NGN was less pronounced than DM. In addition to 
ST2 cells, we used primary BM stromal cells to assess if Cxcl12 expression was affected by 
altered SMAD signaling, by performing qRT-PCR (Fig. 2e). As for ST2 cells, inhibition of 
SMAD-mediated BMP signaling by DM or NGN also induced increased expression of 
Cxcl12 in primary BM stromal cells. These results demonstrate that inhibition of BMP 
signaling enhances the expression of Cxcl12 in cells that belong to the BM niche. Moreover, 
the effect of NGN on Cxcl12 expression suggested that the SMAD-mediated BMP signaling 
was already active in stromal cells, either due to the presence of BMPs in the fetal bovine 
serum (FBS) or due to production of BMPs by these cells.
Expression of Cxcl12 in ST2 cells is controlled in autocrine fashion
While we demonstrated that inhibition of SMAD-dependent BMP signaling in ST2 cells 
enhanced the chemo-attraction of HSPCs and increased CXCL12 production, stimulation via 
BMP7 addition did not have these effects in vitro. Yet, in our in vivo studies, systemic 
induction of SMAD signaling by BMP7 infusion resulted in increased expression and 
secretion of CXCL12. We hypothesized that this discrepancy could be attributed to the 
differences in the expression pattern of BMP receptors in BM niche cells and ST2 cells.
To address this, we first evaluated the expression of Bmp2, Bmp4, Bmp6, Bmp7 and Bmp8a 
in ST2 and primay BM derived lin−CD45− cells (representative of the BM niche) by qRT-
PCR (Fig. 3a). We found high levels of Bmp4 expression in both ST2 cells and in BM niche 
cells. We also analyzed the expression of various BMPR genes (Bmpr1a, Bmpr1b, Acvr1, 
Acvrl1 and BmprII) 36 in ST2 and niche cells (Fig. 3b). We found that Bmpr1a and Bmpr1b, 
known to be responsible for BMP4 binding, were highly expressed in ST2 cells but not in 
Lin−CD45− BM niche cells. This may therefore explain why we found an effect of BMP4 in 
the ST2 cell-based in vitro assay system, but not following systemic infusion. Of note, we 
did not find high levels of transcripts for the ACVR1 gene, the major type-I receptor for 
Khurana et al. Page 7
Stem Cells. Author manuscript; available in PMC 2015 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
BMP7 37 in Lin−CD45− niche cells, even though BMP7 inhibited homing and CXCL12 
levels.
The observation that blocking SMAD signaling via DM and NGN induced CXCL12 
expression in ST2 cells, suggested that CXCL12 expression was regulated in an autocrine 
fashion, and likely via the production of BMP4 by ST2 cells that binds to the BMPR1A and 
BMPR1B receptors, all co-expressed in ST2 cells. To further substantiate this, we used anti-
BMP4 antibodies to neutralize BMP4 present in the FBS or secreted by ST2 cells and 
assessed its effect on Cxcl12 expression (Suppl. Fig. 2). We found that addition of 
neutralizing antibodies against BMP4 significantly increased Cxcl12 expression. We 
confirmed these results by performing knockdown studies for Bmp4 as well as Smad1 and 
Smad5 using an endonuclease prepared siRNA (esi-RNA) approach, which has been 
reported to reduce off-target effects compared with siRNAs 38. We confirmed the 
knockdown of Bmp4, Smad1 and Smad5 by qRT-PCR (Fig. 3c) and western blotting (Fig. 
3d, quantitation in Suppl. Fig. 3). Knockdown of Bmp4, Smad1 or Smad5, resulted in 
decreased expression of Cxcl12 (Fig. 3e), confirming the hypothesis that autocrine BMP4 
signaling is responsible for regulating CXCL12 expression in ST2 cells.
Identification of SMAD binding elements responsible for regulation of Cxcl12 expression
We identified 6 SMAD binding elements (SBEs; CAGACA or TGTCTG) in a region 4kb 
upstream of the transcription start site of the CXCL12 gene (Fig. 4a). We performed ChIP 
assays to determine to which of these SBEs in the CXCL12 promoter SMAD4 binds in 
response to BMP signaling in ST2 cells. ChIP for SMAD4 using the sheared chromatin was 
performed and the immuno-precipitated DNA was used as template to identify the binding 
sites for SMAD4 using primers flanking all 6 SBEs (Suppl. table). For each ChiP 
experiment, signals from isotype control antibody were subtracted from IP signals. Recovery 
of the amplified sequences was quantified as percent of input chromatin. Out of the 6 SBEs, 
we found one site, 2769bp upstream of the start site, significantly enriched in the immuno-
precipitated DNA (Fig. 4b). Importantly, addition of DM that inhibits phosphorylation of R-
SMADs also inhibited binding of SMAD4 to this SBE site in the CXCL12 promoter (Fig. 
4c). To confirm the importance of this SBE site for SMAD4 binding, the sequence was 
deleted from the promoter construct using site-directed mutagenesis. The mutated promoter 
was cloned upstream of the luciferase gene in the pGL3 vector, and transfected in ST2 cells. 
Luciferase assays demonstrated that deletion of the SBE at 2769bp upstream of the 
transcriptional start site in the CXCL12 promoter prevented promoter activation (Fig. 4d). 
Moreover, addition of DM or NGN no longer affected the function of the CXCL12 promoter 
in ST2 cells. These experiments thus confirmed regulation of CXCL12 expression by 
SMAD signaling as deletion of the SBE responsible for SMAD4 binding led to increase in 
basal expression levels of Cxcl12.
Stimulation of SMAD signaling in BM leads to decrease in Cxcl12 expression in the BM 
niche and mobilization of ST-HSCs
As we observed decreased levels of CXCL12 in BM plasma in response to BMP7 infusion, 
we examined whether mobilization of HSPCs was also affected. First, we enumerated the 
number of primitive HSCs, defined as CD150+CD48− KLS cells (SLAM KLS), in the BM 
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of mice 24h after infusion of PBS or BMP7 (Fig 5a). BMP7 injection resulted in a decrease 
in the frequency of primitive HSCs in the BM. To determine if there was any change in 
circulating HSPCs in the PB, we performed methylcellulose colony assays and enumerated 
the frequency of CFCs in PB following PBS or BMP7 injection (Fig. 5b). We observed a 
4.96±1.53 fold (p=0.003) increase in the frequency of circulating CFCs in PB of mice 
infused with BMP7.
As BMP7 increased, even if relatively modestly, the number of circulating CFCs, we 
assessed the ability of HSPCs mobilized by BMP7 to reconstitute hematopoiesis in lethally 
irradiated hosts. MNCs derived from 1ml of PB of CD45.1 mice that were injected 
intravenously with either PBS/BMP7 24 h earlier, along with 100,000 total BM cells from 
CD45.2 mice were transplanted in lethally irradiated CD45.2 animals. Chimerism was 
analyzed every 4 weeks (Fig. 5c). After 4 weeks, we observed engraftment of the PB 
derived cells from BMP7 treated but not control mice in all mice transplanted. Surprisingly, 
PB derived cells from BMP7 treated mice did not contribute to hematopoiesis from 8 weeks 
onwards, indicating that BMP7 mobilizes short-term (ST) HSPCs but not long-term (LT) 
HSCs. After 16 weeks we sacrificed the primary recipients to analyze BM repopulation by 
PB cells from BMP7 or control treated mice. We did not find any contribution of cells from 
BMP7 or control treated mice to the hematopoietic compartment in the BM (Suppl. Fig. 4a) 
confirming the hypothesis that the transplanted cells were indeed ST-HSPCs. Interestingly, 
multi-lineage analysis from the donor derived cells revealed a bias towards lymphoid 
engraftment. The proportion of both B- and T-cells derived from donor-derived cells was 
significantly higher than the recipient’s derived cells (Fig. 5d, Suppl. Fig. 4b). On the other 
hand, myeloid differentiation potential of the donor-derived cells was lower than the 
recipient.
We next examined whether there was any effect of BMP7 infusion on the frequency of 
HSCs within the BM or CXCR4 expression on these cells, which could also lead to an 
increased proportion of circulating HSPCs in the PB (Fig. 6). We harvested BM cells from 
PBS/BMP7 infused mice and assessed the expression of CXCR4 on SLAM KLS cells (Fig. 
6a). We did not observe any change in the expression of CXCR4 on these cells. We also 
assessed the expression of CXCR4 on HSCs that migrated in chemotactic response to ST2 
cells cultured with or without NGN (Suppl. Fig. 5). We did not find any change in CXCR4 
expression on HSCs that migrated towards NGN treated ST2 cells as compared with control 
cells. Finally, we also assessed if there was any effect NGN infusion on the frequency of 
hematopoietic progenitors as well as HSCs within the BM (Fig. 6b–d). We could not detect 
any change in the frequency of HSCPs (lin−c-kit+), KLS or SLAM KLS cells following 
BMP7 infusion. This rules out the possibility that mobilization of hematopoietic progenitors 
was caused by an increased number of HSC within the BM or by changes in the expression 
of CXCR4 expression on these cells.
BMP7 affects Cxcl12 expression specifically in osteoblasts within the BM niche
As it has been demonstrated that deletion of Cxcl12 expression in different cell types of the 
BM niche affects different subsets of HSPCs, we assessed in which cell type within the BM 
niche Cxcl12 expression changed in response to infusion of BMP7. Control or BMP7 treated 
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animals were sacrificed and BM cells were isolated following crushing the hind limb bones 
and treating with collagenase I. Cellular components of the HSC niche were sorted based on 
a compliment of cell surface antigens known to be expressed on these subpopulations 
(Suppl. fig. 6, upper panel): Mesenchymal stromal/stem cells 
(lin−CD45−CD31−CD51+Sca-1+; MSCs), osteoblasts (lin−CD45−CD31−CD51+Sca-1−; 
OBs) and endothelial progenitor cells (lin−CD45−CD31+; EPCs), as published earlier 28. 
The sorted cells were used for RNA isolation followed by amplification and quantitation of 
expression of Cxcl12 using qPCR (Fig. 7a). These studies demonstrated that expression of 
Cxcl12 in EPCs and MSCs was unchanged in response to BMP7 infusion, whereas BMP7 
treatment significantly decreased Cxcl12 expression in osteoblasts. Using FACS we 
confirmed that CXCL12 protein levels were lower in osteoblasts 
(lin−CD45−CD31−CD51+Sca-1−) from BMP7 injected mice compared with control mice 
(Fig. 7b). These results were also confirmed by using collagen type I (Col1) as the marker 
for osteoblasts. Col1-specific antibodies were used to identify osteoblast population in 
lin−CD45−CD31−Sca-1− cells (Suppl. Fig. 6 lower panel).
We also assessed the expression of different BMPR genes on osteoblastic cells by qRT-PCR 
(Fig. 7c) and flowcytometry (Fig. 7d). Sorted osteoblastic cells from control mice were 
subjected to qRT-PCR to examine the expression of various BMPR genes. We found that 
amongst all type I BMPRs analyzed, Acvr1 showed the highest expression. We confirmed 
that ACVR1 was expressed on the cell surface of osteoblasts by flowcytometry (Fig. 7d).
To confirm the effect of BMP signaling on CXCL12 expression, specifically in osteoblasts, 
we used Col1a1-GFP reporter mice. First, we used this system to confirm the phenotypic 
markers of osteoblasts used in experiments described above. We found that 73.42±4.52% of 
Lin−CD45−CD31−CD51+Sca-1− BM cells were also Col1a1-GFP+ (Suppl. Fig. 7a) 
confirming that these phenotypic markers successfully identified osteoblasts. Next, mice 
were infused with either PBS or BMP7, and after 24h all BM cells were harvested by 
enzymatic digestion of crushed bones. The expression of CXCL12 in Col1a1-GFP+ 
osteoblasts was detected by flowcytometry (Fig. 7e). As in earlier experiments, we observed 
a decrease in CXCL12 expression in Col1a1-GFP+ cells following BMP7 infusion. We also 
assessed whether BMP7 treatment led to any change in the number of osteoblasts (Fig. 7f). 
We could not detect a significant change in the number of Col1a1-GFP+ osteoblasts 
following BMP7 infusion as compared with the PBS infused animals within the timespan of 
the experiment. We also used BrdU incorporation assays to assess the proliferation of 
osteoblasts (Suppl. Fig. 7b). Consistent with the fact that the osteoblast number was 
unchanged, we did not see any change in their proliferation status following BMP7/DM 
infusion. Therefore, the effect of altered BMP signaling on CXCL12 expression within the 
BM niche could not be linked to changes in the absolute number of osteoblasts. Thus, we 
conclude that osteoblasts exhibit significantly decreased CXCL12 expression following 
BMP7 infusion in vivo.
Discussion
Although it is well established that BMP signaling is of great importance during fetal 
hematopoiesis, the role of BMP signaling in adult hematopoiesis is less well understood. 
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Others and we have demonstrated that SMAD-dependent BMP signaling is dispensable for 
postnatal HSPC functions 33, as elimination of SMAD1 and SMAD5 expression in HSPCs 
did not affect their ability to sustain hematopoiesis upon transplantation 39. However, BMPs 
are present in the BM microenvironment and it has been shown that conditional inactivation 
of the BMP receptor type IA (BMPRIA) causes expansion of osteoblasts as well as HSPCs, 
indicating an indirect effect of BMPs on adult hematopoiesis 40. We here demonstrated that 
infusion of BMP7 systemically led to decreased homing and engraftment of transplanted 
HSCs while infusion of NGN showed the opposite effect. Screening for important 
hematopoiesis regulators within niche cells identified altered expression of Cxcl12 in 
lin−CD45− BM cells (containing all HSC niche cells). The chemokine CXCL12 mediates 
chemotactic migration of transplanted HSPCs towards the BM niche supporting their 
homing 9. Deletion or inhibition of CD26, an enzyme that cleaves CXCL12, in vivo, leads to 
increased homing and engraftment of transplanted HSCs 28, 41.
Activation of SMAD signaling via infusion of BMP7 (but not BMP4) led to decreased 
Cxcl12 expression and secretion in the BM niche. Correspondingly, we detected increased 
numbers of mobilized HSPCs in the peripheral blood, as demonstrated by increased 
frequency of CFCs in the blood following BMP7 infusion. HSPCs mobilized by G-SCF are 
widely used clinically as a source for transplantation 42. In healthy allogeneic stem cell 
donors, G-CSF results in variable mobilizing efficiency 43 and mobilization of HSPCs to the 
blood in patients for autologous transplantation is especially poor 44, 45. In fact, patients who 
received previous chemo- and/or radio-therapy have a 20–25% risk of failing to mobilize 
HSPCs efficiently 46. Multiple mobilization attempts in patients have been shown to 
adversely affect their quality of life, not to mention the cost of treatment 47. Small molecules 
such as Plerixafor (AMD3100) that interfere with the interaction of HSPCs with their 
microenvironment have been reported to aid in G-CSF mediated mobilization 48, 49. 
Ramirez et al. showed that BIO5192, a small molecule inhibitor of VLA-4, leads to up to 
30-fold increase in PB HSPCs 50. When used along with Plerixafor, it increased the efficacy 
of HSPC mobilization 17-fold more, demonstrating the importance of targeting multiple 
pathways for mobilization. The finding that BMP7 also enhances CFC mobilization may 
therefore be of significant clinical importance.
We used mouse BM stroma-derived ST2 cells (in addition to OP9 and ac11 cells; data not 
presented in this manuscript) as in vitro model of BM niche cells to understand the 
underlying processes that lead to alteration of Cxcl12 expression by SMAD-mediated BMP 
signaling. ST2 cells have been shown to support both myelopoiesis and lymphopoiesis 51. 
We found that BMP4 is highly expressed by ST2 cells, and by using neutralizing antibodies 
we found that BMP4 regulates Cxcl12 expression in an autocrine SMAD-dependent manner. 
This was confirmed by knockdown of Bmp4 or Smad1/5 expression in ST2 cells, which 
resulted in enhanced Cxcl12 expression. Interestingly, while BMP4 secreted by ST2 cells 
affected the expression of Cxcl12, infusion of BMP4 did not affect Cxcl12 expression in 
vivo; in contrast, BMP7 infusion did affect Cxcl12 expression in vivo. This could be due to 
differences in the expression of the BMPRs between ST2 cells and BM niche cells. While 
ST2 cells expressed Bmpr1a and Bmpr1b as type I BMP receptors, osteoblasts within the 
BM niche expressed significantly higher levels of Acvr1, which is known to act as the main 
receptor for BMP7 37. These findings likely explain why infusion of BMP7 only affects 
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CXCL12 expression in osteoblasts, while addition of BMP7 to ST2 cells that do not express 
ACVR1 does not affect CXCL12 expression.
Upon ligand binding, the R-SMADs (SMAD1/5) are phosphorylated by BMP type I 
receptors and bind to the common SMAD (SMAD4) 52. This complex is then translocated to 
the nucleus and controls transcription of various genes, either by binding to the promoter 
regions themselves or by associating with other DNA binding transcription factors 53. The 
crystal structure of the complex formed between the SMAD DNA binding domain, MH1, 
and SMAD binding elements (SBEs) identified the minimal SBE sequence to be GTCT (or 
its complementary CAGA) 54. In many instances SBEs have been reported to have 1–2 extra 
bases 55. Hence, we used CAGACA to determine if SBEs are present in the CXCL12 
promoter region. We identified 6 SBEs in the promoter region of Cxcl12. The SBE at 
2769bp upstream of the transcriptional start site in the CXCL12 promoter is responsible for 
SMAD-mediated repression of Cxcl12 expression in ST2 cells.
The CXCL12-CXCR4 signaling axis plays not only a major role in retention of HSCs in the 
BM but also in maintaining the HSC pool 10, which explains why disruption of the CXCR4/
CXCL12 axis leads to HSPC mobilization and HSC exhaustion 56. Our experiments showed 
mobilization of only ST-HSPCs in response to infusion of BMP7. Two recent reports 
suggest the importance of the cell type in which CXCL12 is expressed on HSC 
maintenance 13, 14. These studies demonstrate that various cells in the BM including 
mesenchymal stromal cells, perivascular stromal cells, endothelial cells, osteoblasts as well 
as some hematopoietic cells express Cxcl12. Conditional elimination of Cxcl12 from Tie2+ 
endothelial cells in the BM affects HSC maintenance. When Cxcl12 expression was 
eliminated from leptin receptor (Lepr)-positive perivascular stromal cells, no effect on HSC 
maintenance was seen even if there was a significant increase in circulating HSPCs, along 
with higher numbers of HSPCs in spleen. Cxcl12 deletion from Prx1-positive mesenchymal 
stromal cells significantly decreased HSC maintenance in the BM. However, elimination of 
Cxcl12 expression in Osx-positive osteoprogenitors or Col1a1[2.3kb]-positive osteoblasts 
did not affect overall HSC maintenance but had a specific effect on lymphoid progenitor 
numbers 13, 14. Our data supported these results as the hematopoietic progenitors mobilized 
following BMP7 infusion demonstrated lymphoid bias when transplanted in irradiated hosts.
Altogether, our data presents a novel mechanism by which CXCL12 expression is regulated 
in the BM niche. We presented evidence that by increasing CXCL12 production by 
inhibition of SMAD signaling within the BM niche, it was possible to increase homing and 
engraftment potential of transplanted HSPCs. Contrary to this, decrease in CXCL12 
expression led to mobilization of at least the ST-HSPCs.
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Figure 1. Inhibition of SMAD signaling in BM leads to enhanced engraftment of transplanted 
HSCs
(A) 50,000 BM cells derived from CD45.1 mice were transplanted into sub-lethally 
irradiated CD45.2 animals pre-infused (24h prior to transplantation) with either PBS or 
NGN (Noggin). Donor derived chimerism was analyzed every 4 weeks. (B) After 12 weeks, 
primary recipients were sacrificed and 1 million BM cells were transplanted in lethally 
irradiated CD45.2 secondary recipients. PB chimerism was analyzed after 12 weeks. n=12, * 
p<0.05 (C) 100,000 BM cells derived from CD45.1 mice were injected in lethally irradiated 
CD45.2 hosts pre-infused with PBS, BMP4, BMP7 or NGN. The fraction of transplanted 
CFU-Cs that homed into the BM after 16h of transplantation was assessed. n=8, * p<0.05 
(D) The effect of BMP7/NGN on Cxcl12 expression in non-hematopoietic BM cells was 
assessed by qRT-PCR. Mice were injected with PBS/BMP7/NGN, and after 24h, the 
lin−CD45− fraction of total BM cells was isolated using MACS. Expression of SMAD target 
genes (Id2, Id3 and Runx2) as well as Cxcl12 was analyzed by qRT-PCR. n=6, * p<0.05 
(E,F) Twenty four hours after BMP7/NGN infusion, PB and BM plasma was isolated and 
levels of CXCL12 in the plasma was quantified by ELISA and compared with PBS injected 
controls. n=6–8, * p<0.04
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Figure 2. Inhibition of SMAD-mediated BMP signaling enhances CXCL12 expression in BM 
stromal cells
(A) ST2 cells cultured with BMP4/BMP7/NGN/DM were used to assess migration of 
HSPCs using a trans-well system n=5, * p=0.02 (NGN= noggin; DM = dorsomorhin). (B) 
The effect of SMAD signaling on Cxcl12 expression was analyzed by qRT-PCR on ST2 
cells cultured with/without BMP4/BMP7 or inhibitors DM/NGN. n=9, * p=0.003 (C) ST2 
cell were cultured with/without DM for 48h and culture supernatant was used to quantify 
secreted CXCL12 by ELISA. n=4, *p=0.04 (D) The CXCL12 promoter was cloned 
upstream of the luciferase gene in the pGL3 plasmid and ST2 cells were transfected with the 
vector. Effect of BMP7 or NGN/DM on Cxcl12 expression in transfected cells was assessed 
by Luciferase assay. n=4, * p<0,05 (E) Primary BM stromal cells were expanded and 
cultured in the presence of BMP4/BMP7/DM/NGN and the effect on Cxcl12 expression was 
compared with control by performing qRT-PCR. n=4, * p<0,05
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Figure 3. SMAD-mediated autocrine BMP signaling is responsible for regulation of Cxcl12 
expression
(A) Transcript levels of various Bmp’s and (B) Bmpr’s in ST2 cells and BM derived 
lin−CD45− cells were analyzed by qRT-PCR. (C,D) Expression of Smad1, Smad5 and 
Bmp4 in ST2 cells was inhibited using esiRNA-mediated knockdown. Efficiency of 
knockdown was quantified using qRT-PCR (C) and (D) immuno-blotting. n=4, * p<0.02 (E) 
Effect of Bmp4 and Smad1/5 knockdown on Cxcl12 expression in ST2 cells was assessed 
using a luciferase promoter assay. n=4, * p<0.04
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Figure 4. Identification of SMAD binding element responsible for regulation of BMP-mediated 
CXCL12 expression
(A) Graphical representation of CXCL12 promoter region that contains 6 putative SBEs. 
Primers were designed to detect each of the individual SBEs following ChIP analysis. (B) 
Levels of the 6 SBEs from CXCL12 promoter immunoprecipitated using SMAD4 antibodies 
measured following PCR amplification of DNA fragments. Signals from isotype controls 
antibodies used for each ChiP were subtracted from the SMAD4 IP signals and the fold 
enrichment ratios of ChIP enriched versus total input DNA were represented. (C) Effect of 
DM treatment of ST2 cells on SMAD4 binding to SBE4 as quantified by qChIP analysis. 
Khurana et al. Page 19
Stem Cells. Author manuscript; available in PMC 2015 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
n=4, * p=0.01 (D) The SBE4 was deleted from the promoter of CXCL12 by PCR based 
mutagenesis, and the mutated (Mut-Cxcl12 pGL3) or wild-type (Cxcl12-pGL3) promoter 
was transfected in ST2 cells to assess the effect of DM and NGN on Cxcl12 expression in 
ST2 cells vector by luciferase assays. n=4, * p<0.04
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Figure 5. Stimulation of SMAD signaling in the bone marrow leads to decreased Cxcl12 
expression in the BM niche and mobilization of ST-HSCs
Mice were treated with PBS/BMP7 by iv injection in the tail vein. (A) After 24h, the 
frequency of primitive HSCs in the BM was assessed by performing flowcytometric 
detection of CD150+CD48− KLS cells. (B) Following PBS/BMP7 infusion, the frequency of 
circulating HSPCs was quantified by methylcellulose based colony formation assays. The 
number of CFCs per ml of PB was plotted. n=8, *p=0.007. (C) PB derived MNCs from 
PBS/BMP7 injected CD45.1 mice were transplanted along with 100,000 total BM cells from 
CD45.2 mice in lethally irradiated CD45.2 mice. Donor derived chimerism was analyzed 
every 4 weeks. n=12, * p=0.0015 (D) Multi-lineage potential of the donor derived cells was 
examined by using antibodies against CD11b/Gr-1 (macrophage/granulocyte), B-220 (B-
lymphocytes), CD4/CD8 (T-lymphocytes) in addition to CD45.1/CD45.2. Proportion of 
differentiated cells in each lineage within CD45.1 cell fraction of PB after 4 weeks of 
transplantation is presented. n=8, * p<0.05.
Khurana et al. Page 21
Stem Cells. Author manuscript; available in PMC 2015 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6. BMP7 infusion does not change expression of CXCR4 expression or frequency of HSCs
(A) Mice with infused with PBS/BMP7 and BM cells were harvested after 24h. CXCR4 
expression on lin−c-kit+Sca-1+CD48−CD150+ (SLAM KLS) cells was analyzed by 
flowcytometry using specific antibodies. (B–D) Number of HSPCs, KLS cells and SLAM 
KLS cells per million of the total BM cells was quantified by flowcytometry. n=6, ns p>0.05
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Figure 7. BMP7 infusion results in decreased Cxcl12 expression specifically in osteoblasts
(A) BM cells were harvested from mice treated with or without BMP7 for 24h. Cellular 
components of HSC niche; endothelial progenitor cells (EPCs), mesenchymal stroma/stem 
cells (MSCs) and osteoblasts (Obs) were isolated by FACS. Total RNA was isolated from 
EPCs, MSCs and Obs, and subjected to qRT-PCR for Cxcl12 and levels compared between 
cells derived from BMP7 treated or control mice (n=3, p=0.04). (B) CXCL12 expression in 
Obs in BM cells of mice infused with PBS/BMP7 was analyzed by flowcytometry (n=4). 
(C) Gene expression levels of BMP receptors assessed by qRT-PCR on amplified RNA 
obtained from osteoblasts sorted from BM. (D) Flowcytometric analysis confirming 
expression of the BMP7 receptor Acvr1 in comparison to BMPR1a and BMPR1b in 
osteoblasts. (E,F) Col1a1-GFP mice infused with/without BMP7, were sacrificed and BM 
cells were harvested by enzymatic digestion. Expression of CXCL12 in Col1a1-GFP+ 
osteoblasts (E) as well their proportion in BM cells (F) was examined by flowcytometry 
using specific antibodies.
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